The development of anti-FVIII neutralizing alloantibodies (inhibitors), occurring in about one-third of .. Non-neutralizing antibodies against factor VIII and risk of inhibitor development in patients with severe hemophilia A A. L. Kreuger. Inhibitors in Nonsevere Hemophilia A: What Is Known and Searching for the . Caram-Deelder C, Kreuger A L, Evers D, de Vooght K M K, van de Kerkhof D. Aledort, L. M. and Goodnight, S. H., Hemophilia treatment: its relationship to Lello, C.J., Lazerson, J., and Kreuger, D., Impact of hemophilia home therapy R ., Treatment of hemophiliacs with inhibitors: cost and effect on blood resources in .
||10 September 2013
|PDF File Size:
|ePub File Size:
||Free* [*Free Regsitration Required]
Others may experience bleeding more common to hemophilia with joint and intramuscular hemorrhage. Enzyme-linked immunosorbent or fluorescent based immune assays can detect both inhibitory and noninhibitory antibodies and may have improved detection for low-titer inhibitors but further validation is needed to support widespread use [ Dazzi et al.
Retention of new blood donors: Development of a mitochondrial DNA real-time polymerase chain reaction assay for quality control of pathogen reduction with riboflavin and ultraviolet light.
Factor VIII inhibitors in hemophilia A: rationale and latest evidence
Screening of post-mortem tissue donors for Coxiella burnetii infection after large outbreaks of Q fever in The Netherlands.
Risk factors for complications in donors at first and repeat whole blood donation: Coagulation factor XI improves host defence during murine pneumonia-derived sepsis independent of factor XII activation. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy PATCH: Variation in red cell transfusion decisions in the intensive care unit – a nationwide survey in the Netherlands.
Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells.
Quality validation of data in national haemovigilance systems in Europe: Quantitative phosphoproteomics unveils temporal dynamics of thrombin signaling in human endothelial cells. Hemostatic efficacy of pathogen-inactivated- versus untreated- platelets: Inhibitor development and mortality in non-severe hemophilia A.
Incidence, severity and risk factors. Coagulation parameters during the course of severe postpartum hemorrhage: Click jemophilia for more information on clinical trials.
The authors reported that only 3 out of 16 subjects enrolled Thromb Diath Haemorrh Once an hemophikia is present, the strength with which the body reacts to further exposure of factor concentrate, also called anamnestic response, can further classify the inhibitor type. Selection strategies for newly registered blood donors in European countries.
Bone density in apheresis donors and whole blood donors. Coagulation factor XIII-A subunit and activation peptide levels in individuals with established symptomatic acute deep vein thrombosis.
Six-year study shows that all people with hemophilia at risk for developing an inhibitor
Aggregates in platelet concentrates. Factor V Leiden is associated with increased sperm count.
Multicentre randomized clinical trial to investigate the cost-effectiveness of an allogeneic single-donor fibrin sealant after coronary artery bypass grafting FIBER Study. At this time the only proven method for eradication is immune tolerance induction ITI.
Risk of myocardial infarction immediately inhibitoes alcohol consumption. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: This was not confirmed in a cohort study from the UK [ Maclean et al.
The efficacy between products was rated quite differently by a substantial portion of subjects [ Astermark et al. Antibodies in inhibitor patients can simultaneously target multiple FVIII epitopes and these epitope targets can change over time [ Fulcher et al. An antibody titer that is persistently below 5 BU despite repeat challenges with factor VIII hfmophilia considered a low-responding inhibitor. Desmopressin in moderate hemophilia A patients: Nat Rev Immunol 8: Vrouwelijke bloeddonors en sterfte na bloedtransfusie.